Combination Anti-IgE and Anti-IL5 Therapy in a Pediatric Patient With Severe Persistent Asthma

Biologic agents, including anti-immunoglobulin E (omalizumab) and anti-interleukin 5 (mepolizumab), target different mediators involved in the inflammatory process and may work synergistically to decrease symptoms in patients with severe asthma. Here we describe a 12-year-old female on 2 biologic ag...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2021, Vol.26 (3), p.306-310
Hauptverfasser:	Fox, Haley M, Rotolo, Shannon M
Format:	Report
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!